Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$52.73

-0.19 (-0.36%)

08:48
11/27/18
11/27
08:48
11/27/18
08:48

Bristol-Myers trial failure has minimal financial impact, says William Blair

William Blair analyst Matt Phipps sees a minimal financial impact to Bristol-Myers Squibb from the failure of the CheckMate-451 trial but he admits that investor sentiment "could use a boost." While this is unfortunate and is the second recent failure of Opdivo in small-cell lung cancer, the financial impact is limited given the small market opportunity and already announced positive competitive results in the frontline setting, Phipps tells investors in a research note. The analyst removed potential sales for small-cell lung cancer post-chemotherapy from his Opdivo estimates, decreasing his 2020 Opdivo estimate by 0.3% to $7.57B and 2021 estimate by 0.6% to $8.92B. His 2020 earinngs per share estimate goes to $4.48 from $4.49 and 2021 estimate goes to $4.94 from $4.96. Phipps keeps an Outperform rating on Bristol-Myers.

  • 27

    Nov

  • 29

    Nov

  • 20

    May

BMY Bristol-Myers
$52.73

-0.19 (-0.36%)

11/27/18
BMOC
11/27/18
NO CHANGE
Target $56
BMOC
Market Perform
Bristol-Myers price target lowered to $56 at BMO Capital on execution concern
BMO Capital analyst Alex Arfaei lowered his price target on Bristol-Myers to $56 and kept his Market Perform rating, saying the "surprising" failure of CM-451 and CM-331 suggests that the company "will likely not be competitive" in small-cell lung cancer. The analyst adds that the findings represent another immuno-oncology setback for the company that may increase investor concerns about Bristol-Myers' R&D execution, which has to improve for him to become more constructive on the stock.
11/19/18
WELS
11/19/18
NO CHANGE
WELS
Pfizer price hikes may bring industry scrutiny, says Wells Fargo
Pfizer's (PFE) plans to raise prices on a host of medicines may put the drug industry "further in the crosshairs of an administration and Congress that is set on lowering drug prices," Wells Fargo analyst David Maris tells investors in a research note. The analyst points out that Pfizer earlier this year was criticized by the Trump administration for drug price increases, and as a result, it rolled the price increases back. However, Pfizer's new price increases "are not egregious" and its advance warning may be an attempt to see if minor price increases will also bring the administration's rebuke, says Maris. Nonetheless, given how public the administration's previous rebuke was, the analyst thinks Pfizer's confirmation Friday could "enflame the debate around drug pricing, especially since it comes less than two weeks following an election that resulted in Democrat control of the House with many having run on a drug-price-controls/Medicare-for-All platforms." Other large drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
11/08/18
JEFF
11/08/18
NO CHANGE
Target $73
JEFF
Buy
Nektar price target lowered to $73 from $103 at Jefferies
Jefferies analyst David Steinberg lowered his price target for Nektar Therapeutics (NKTR) to $73 after reducing his assumptions for NKTR-214 to reflect a potentially prolonged delay in non-small-cell lung carcinoma. The analyst, however, keeps a Buy rating on the shares following the company's Q3 results. He points out that Nektar's partnership with Bristol-Myers (BMY) as well as its other collaborations are ramping up.
11/05/18
HCWC
11/05/18
NO CHANGE
Target $47
HCWC
Neutral
Nektar price target lowered to $47 from $54 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Nektar Therapeuticsless than (NKTR) to $47 and keeps a Neutral rating on the shares. While the Phase 3 trial of Opdivo plus NKTR-214 is welcome news, the company faces a crowded frontline renal cell carcinoma treatment landscape and stiff commercial hurdles, Chattopadhyay tells investors in a research note. He believes that unless the NKTR-214 plus Opdivo combination is meaningfully superior to the Opdivo and Yervoy combination, Bristol-Myers (BMY) "may not be willing to muscle the commercial launch, given the cannibalization of its existing franchise."

TODAY'S FREE FLY STORIES

NET

Cloudflare

$17.96

(0.00%)

, AMZN

Amazon.com

$1,837.49

-6 (-0.33%)

07:40
09/15/19
09/15
07:40
09/15/19
07:40
On The Fly
Opening Day: Cloudflare jumps in market debut »

Shares of Cloudflare…

NET

Cloudflare

$17.96

(0.00%)

AMZN

Amazon.com

$1,837.49

-6 (-0.33%)

MSFT

Microsoft

$137.21

-0.33 (-0.24%)

STSA

Satsuma Pharmaceuticals

$16.61

(0.00%)

SWTX

SpringsWorks Therapeutics

$22.75

(0.00%)

SDC

SmileDirectClub

$18.68

1.8 (10.66%)

TXG

10x Genomics

$53.80

0.85 (1.61%)

PTON

Peloton

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

NVST

Envista

$0.00

(0.00%)

XGN

Exagen

$0.00

(0.00%)

DDOG

Datadog

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

NDAQ

Nasdaq

$99.51

0.5 (0.51%)

DHR

Danaher

$141.02

-0.84 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

  • 17

    Sep

  • 17

    Sep

  • 27

    Oct

  • 07

    Nov

  • 18

    Sep

  • 19

    Sep

  • 26

    Sep

04:55
09/15/19
09/15
04:55
09/15/19
04:55
Conference/Events
SunTrust retail/consumer goods analysts to hold a dinner meeting »

Retail/Consumer Goods…

ABT

Abbott

$84.25

-0.96 (-1.13%)

, ADPT

Adaptive Biotechnologies

$43.28

3.49 (8.77%)

13:22
09/14/19
09/14
13:22
09/14/19
13:22
Conference/Events
William Blair diagnostic products/med tech analyst to hold a group luncheon »

Diagnostic Products &…

ABT

Abbott

$84.25

-0.96 (-1.13%)

ADPT

Adaptive Biotechnologies

$43.28

3.49 (8.77%)

BDX

Becton Dickinson

$260.68

-1.41 (-0.54%)

COO

Cooper Companies

$301.95

-3 (-0.98%)

EXAS

Exact Sciences

$106.72

-1.99 (-1.83%)

GH

Guardant Health

$77.54

0.49 (0.64%)

NEO

NeoGenomics

$21.34

-1.22 (-5.41%)

LMNX

Luminex

$22.62

0.1 (0.44%)

HAE

Haemonetics

$125.55

-0.31 (-0.25%)

STAA

STAAR Surgical

$29.21

0.415 (1.44%)

QGEN

Qiagen

$33.97

-0.105 (-0.31%)

NVTA

Invitae

$21.70

-0.2 (-0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Sep

  • 13

    Nov

  • 05

    Dec

CRTO

Criteo

, TWTR

Twitter

13:19
09/14/19
09/14
13:19
09/14/19
13:19
Conference/Events
FBN Securities Tech/Internet analyst to hold a group luncheon »

Technology & Internet…

CRTO

Criteo

TWTR

Twitter

SNAP

Snap

GOOGL

Alphabet Class A

FB

Facebook

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 17

    Sep

  • 20

    Sep

  • 24

    Sep

  • 27

    Oct

T

AT&T

$37.90

-0.46 (-1.20%)

09:06
09/14/19
09/14
09:06
09/14/19
09:06
Periodicals
AT&T stock already benefiting from activist involvement, Barron's says »

AT&T 's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

DIS

Disney

$138.00

0.44 (0.32%)

, NFLX

Netflix

$294.00

5.08 (1.76%)

09:04
09/14/19
09/14
09:04
09/14/19
09:04
Periodicals
Consumers might not be as in love with Apple TV+ as Wall Street, Barron's says »

Following Apple's…

DIS

Disney

$138.00

0.44 (0.32%)

NFLX

Netflix

$294.00

5.08 (1.76%)

AAPL

Apple

$218.71

-4.4 (-1.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Oct

UAL

United Airlines

$91.37

1.99 (2.23%)

08:58
09/14/19
09/14
08:58
09/14/19
08:58
Periodicals
United Airlines could get boost after short squeeze, Barron's says »

United Airlines stock has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

BAC

Bank of America

$30.12

0.44 (1.48%)

08:55
09/14/19
09/14
08:55
09/14/19
08:55
Periodicals
Bank of America stock worth betting on, Barron's says »

Amid talk of a coming…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

TPR

Tapestry

$25.16

-0.43 (-1.68%)

08:49
09/14/19
09/14
08:49
09/14/19
08:49
Periodicals
Coach parent's turnaround could be coming, Barron's says »

Even in a rough year for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UHAL

Amerco

$379.63

4.21 (1.12%)

08:45
09/14/19
09/14
08:45
09/14/19
08:45
Periodicals
U-Haul parent stock 'a better-kept secret,' Barron's says »

Amerco (UHAL), owner of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CP

Canadian Pacific

$228.59

-1.38 (-0.60%)

, CNI

Canadian National

$92.13

-0.31 (-0.34%)

08:41
09/14/19
09/14
08:41
09/14/19
08:41
Periodicals
Railroad stocks struggling as challenges increase, Barron's says »

North American railroads…

CP

Canadian Pacific

$228.59

-1.38 (-0.60%)

CNI

Canadian National

$92.13

-0.31 (-0.34%)

UNP

Union Pacific

$171.49

3.81 (2.27%)

CSX

CSX

$72.50

0.96 (1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

MO

Altria Group

$42.01

-0.77 (-1.80%)

, BTI

British American Tobacco

$36.76

-1.21 (-3.19%)

08:06
09/14/19
09/14
08:06
09/14/19
08:06
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

MO

Altria Group

$42.01

-0.77 (-1.80%)

BTI

British American Tobacco

$36.76

-1.21 (-3.19%)

IMBBY

Imperial Brands

$0.00

(0.00%)

PM

Philip Morris

$73.01

-1.89 (-2.52%)

REGI

Renewable Energy

$15.90

0.57 (3.72%)

PSX

Phillips 66

$102.77

0.66 (0.65%)

MPC

Marathon Petroleum

$53.29

0.1 (0.19%)

VLO

Valero

$85.53

1.84 (2.20%)

EVA

Enviva

$31.21

0.06 (0.19%)

AMTX

Aemetis

$1.00

0.14 (16.28%)

PEIX

Pacific Ethanol

$0.78

0.0322 (4.29%)

GPP

Green Plains Partners

$13.18

0.17 (1.31%)

DK

Delek US

$35.91

-0.6 (-1.64%)

HFC

HollyFrontier

$51.41

0.71 (1.40%)

TSO

Tesoro

$0.00

(0.00%)

WNR

Western Refining

$0.00

(0.00%)

T

AT&T

$37.90

-0.46 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 23

    Oct

  • 24

    Oct

  • 31

    Oct

  • 12

    Nov

GLD

SPDR Gold Shares

$140.19

-1.14 (-0.81%)

17:58
09/13/19
09/13
17:58
09/13/19
17:58
Hot Stocks
SPDR Gold Shares holdings fall to 874.51MT from 880.37MT »

This is the second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBVT

DBV Technologies

$10.22

0.595 (6.18%)

, AIMT

Aimmune

$24.66

(0.00%)

17:57
09/13/19
09/13
17:57
09/13/19
17:57
Hot Stocks
Breaking Hot Stocks news story on DBV Technologies, Aimmune »

DBV Technologies falls 2%…

DBVT

DBV Technologies

$10.22

0.595 (6.18%)

AIMT

Aimmune

$24.66

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

AIMT

Aimmune

$24.66

(0.00%)

17:55
09/13/19
09/13
17:55
09/13/19
17:55
Hot Stocks
FDA committee votes to support use of Aimmune's Palforzia for peanut allergy »

Aimmune Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

ZAYO

Zayo Group

$33.82

-0.05 (-0.15%)

17:39
09/13/19
09/13
17:39
09/13/19
17:39
Hot Stocks
Zayo Group CEO sells 1M common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

T

AT&T

$37.90

-0.46 (-1.20%)

, MO

Altria Group

$42.01

-0.77 (-1.80%)

17:38
09/13/19
09/13
17:38
09/13/19
17:38
Periodicals
CNN to longer run Juul ads, Daily Beast reports »

AT&T's (T) CNN…

T

AT&T

$37.90

-0.46 (-1.20%)

MO

Altria Group

$42.01

-0.77 (-1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

BAS

Basic Energy

$1.87

-0.08 (-4.10%)

17:34
09/13/19
09/13
17:34
09/13/19
17:34
Hot Stocks
Basic Energy CEO T.M. Patterson to leave company »

Basic Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

XBIO

Xenetic

$1.61

-0.04 (-2.42%)

17:28
09/13/19
09/13
17:28
09/13/19
17:28
Syndicate
Breaking Syndicate news story on Xenetic »

Xenetic files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$218.71

-4.4 (-1.97%)

, DIS

Disney

$138.00

0.44 (0.32%)

17:22
09/13/19
09/13
17:22
09/13/19
17:22
Hot Stocks
Disney CEO Bob Iger resigns from Apple board of directors »

In a regulatory filing,…

AAPL

Apple

$218.71

-4.4 (-1.97%)

DIS

Disney

$138.00

0.44 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

PHG

Philips

$47.79

0.19 (0.40%)

17:21
09/13/19
09/13
17:21
09/13/19
17:21
Hot Stocks
Philips awarded maximum $400M Defense Logistics Agency contract »

Philips has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBSE

NeuBase Therapeutics

$5.70

-0.04 (-0.70%)

17:20
09/13/19
09/13
17:20
09/13/19
17:20
Syndicate
Breaking Syndicate news story on NeuBase Therapeutics »

NeuBase Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

KDMN

Kadmon

$2.80

-0.015 (-0.53%)

17:18
09/13/19
09/13
17:18
09/13/19
17:18
Syndicate
Breaking Syndicate news story on Kadmon »

Kadmon files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KDMN

Kadmon

$2.80

-0.015 (-0.53%)

17:18
09/13/19
09/13
17:18
09/13/19
17:18
Syndicate
Breaking Syndicate news story on Kadmon »

Kadmon files $200M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$198.82

1.22 (0.62%)

17:17
09/13/19
09/13
17:17
09/13/19
17:17
Hot Stocks
Raytheon awarded $427.3M Army procurement contract »

Raytheon was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.